Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 9:29 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,455 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Hepatic Cancer Clear all
Completed Phase 2 Interventional Results available

Selumetinib in Treating Patients With Biliary Cancer That Cannot Be Removed By Surgery

NCT00553332
View directory record Official record
Conditions
Liver and Intrahepatic Biliary Tract Cancer, Recurrent Extrahepatic Bile Duct Cancer, Unresectable Extrahepatic Bile Duct Cancer
Interventions
selumetinib, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
7
States / cities
Tampa, Florida • Atlanta, Georgia • Ann Arbor, Michigan + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2016 · Synced Oct 21, 2026, 9:29 AM EDT
Terminated No phase listed Observational

Viral & Host Factors Associated With Hepatitis B Virus-related Hepatocellular Carcinoma

NCT00767936
View directory record Official record
Conditions
Liver Cancer, Hepatitis B, Hepatitis C, Hepatobiliary Cancers Liver, Hepatobiliary Cancers
Interventions
Not listed
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older · Male only
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jun 29, 2016 · Synced Oct 21, 2026, 9:29 AM EDT
Completed Phase 3 Interventional

Combination Chemotherapy in Treating Patients With Liver Metastases From Colorectal Cancer

NCT00002716
View directory record Official record
Conditions
Colorectal Cancer, Metastatic Cancer
Interventions
dexamethasone, floxuridine, fluorouracil, leucovorin calcium, laparotomy, conventional surgery
Drug · Procedure
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2006
U.S. locations
11
States / cities
Cedar Rapids, Iowa • Des Moines, Iowa • Papillion, Nebraska + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2016 · Synced Oct 21, 2026, 9:29 AM EDT
Active, not recruiting Not applicable Interventional Results available

PORTAL: Patient-reported Outcomes After Routine Treatment of Atypical Lesions

NCT03070236
View directory record Official record
Conditions
Breast Cancer
Interventions
Survey
Other
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
912 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2030
U.S. locations
6
States / cities
Boston, Massachusetts • Newton, Massachusetts • Weymouth, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2026 · Synced Oct 21, 2026, 9:29 AM EDT
Completed Not applicable Interventional

Multidisciplinary Inpatient Palliative Care Intervention

NCT00325611
View directory record Official record
Conditions
Cerebrovascular Accident, Cancer, Coronary Arteriosclerosis, Heart Failure, Congestive, Diabetes Mellitus, Acquired Immunodeficiency Syndrome, Failure to Thrive, Pulmonary Disease, Chronic Obstructive, Dementia, Kidney Failure, Chronic, Pneumonia, Liver Failure, Renal Failure, Respiratory Failure, Stroke
Interventions
Multidisciplinary palliative care team met with patient
Behavioral
Lead sponsor
Kaiser Permanente
Other
Eligibility
18 Years and older
Enrollment
550 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated May 15, 2006 · Synced Oct 21, 2026, 9:29 AM EDT
Completed Phase 2 Interventional

Isolated Hepatic Perfusion With Melphalan Followed by Combination Chemotherapy in Treating Patients With Unresectable Liver Metastases From Colorectal Cancer

NCT00103298
View directory record Official record
Conditions
Colorectal Cancer, Metastatic Cancer
Interventions
FOLFOX regimen, fluorouracil, isolated perfusion, leucovorin calcium, melphalan, oxaliplatin
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 20, 2013 · Synced Oct 21, 2026, 9:29 AM EDT
Approved For Marketing No phase listed Expanded access

TheraSphere® for Treatment of Unresectable Hepatocellular Carcinoma

NCT00906984
View directory record Official record
Conditions
Hepatocellular Carcinoma, Liver Cancer, Liver Neoplasm, Primary Liver Cancer
Interventions
TheraSphere
Device
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Jan 8, 2024 · Synced Oct 21, 2026, 9:29 AM EDT
Terminated Phase 2 Interventional Results available

Study of Stereotactic Body Radiation Therapy Using Tomotherapy for Metastatic Tumors to the Liver

NCT01030757
View directory record Official record
Conditions
Liver Cancer
Interventions
Tomotherapy treatment
Radiation
Lead sponsor
New Mexico Cancer Research Alliance
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Jul 7, 2015 · Synced Oct 21, 2026, 9:29 AM EDT
Withdrawn Phase 2 Interventional

Randomized Phase II Trial of Chemoembolization and Sorafenib

NCT02908165
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
conventional TACE in combination with sorafenib, administered on a continuous schedule, conventional TACE in combination with sorafenib, administered on a sequential schedule
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 10, 2018 · Synced Oct 21, 2026, 9:29 AM EDT
Enrolling by invitation Not applicable Interventional

Getting To Implementation: Improving Cancer Screening for Veterans

NCT06458998
View directory record Official record
Conditions
Cancer of Liver, Cancer of Colon, Cirrhosis
Interventions
Patient Navigation, Implementation Facilitation
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
30,300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Oct 21, 2026, 9:29 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome

NCT04792463
View directory record Official record
Conditions
Uveal Melanoma, Cutaneous Melanoma, BAP1 Gene Mutation, Renal Cell Carcinoma, Mesothelioma, Hepatocellular Carcinoma, Cholangiocarcinoma, Meningioma Atypical
Interventions
Not listed
Lead sponsor
Mohamed Abdel-Rahman
Other
Eligibility
Not listed
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2027
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 21, 2026, 9:29 AM EDT
Completed Early Phase 1 Interventional Results available

A Pilot Study of Trans Arterial Chemoembolization (TACE), Followed by Stereotactic Radiation Therapy (SBRT) for Patients With Hepatocellular Carcinoma

NCT01247298
View directory record Official record
Conditions
Hepatocellular Carcinoma (HCC)
Interventions
Stereotactic Body Radiation Therapy (SBRT)
Combination Product
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Aug 21, 2017 · Synced Oct 21, 2026, 9:29 AM EDT
Recruiting Phase 3 Interventional

Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial

NCT07166406
View directory record Official record
Conditions
Advanced Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8
Interventions
Atezolizumab, Bevacizumab, Biospecimen Collection, Computed Tomography, Durvalumab, Ipilimumab, Magnetic Resonance Imaging, Nivolumab, Positron Emission Tomography, Questionnaire Administration, Stereotactic Body Radiation Therapy, Tremelimumab
Biological · Procedure · Other + 1 more
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older
Enrollment
226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2034
U.S. locations
138
States / cities
Berkeley, California • Cameron Park, California • Fremont, California + 108 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 21, 2026, 9:29 AM EDT
Terminated Early Phase 1 Interventional

Pilot Study Sorafenib as Bridge to Orthotopic Liver Transplantation (OLT)

NCT01337492
View directory record Official record
Conditions
Carcinoma, Hepatocellular
Interventions
Nexavar
Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 21, 2012 · Synced Oct 21, 2026, 9:29 AM EDT
Terminated Phase 1Phase 2 Interventional

Anti-CTLA4-NF mAb (BMS986218), Nivolumab, and Stereotactic Body Radiation Therapy for the Treatment of Metastatic Solid Malignancies

NCT04785287
View directory record Official record
Conditions
Advanced Lung Carcinoma, Advanced Malignant Solid Neoplasm, Malignant Adrenal Gland Neoplasm, Metastatic Liver Carcinoma, Metastatic Lung Carcinoma, Metastatic Malignant Solid Neoplasm, Stage III Liver Cancer, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Liver Cancer, Stage IV Lung Cancer AJCC v8, Stage IVA Liver Cancer, Stage IVA Lung Cancer AJCC v8, Stage IVB Liver Cancer, Stage IVB Lung Cancer AJCC v8
Interventions
Anti-CTLA4 Monoclonal Antibody BMS-986218, Nivolumab, Stereotactic Body Radiation Therapy
Biological · Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 3, 2026 · Synced Oct 21, 2026, 9:29 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Sorafenib and TRC105 in Hepatocellular Cancer

NCT01306058
View directory record Official record
Conditions
Hepatoma, Liver Neoplasms, Adenoma, Liver Cell, Carcinoma, Hepatocellular, Liver Neoplasms, Experimental
Interventions
TRC 105, Sorafenib
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 99 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 23, 2019 · Synced Oct 21, 2026, 9:29 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

STOP HCC: Mailed HCV Treatment Outreach Program for HCC Prevention for Elevated LFTs

NCT04395118
View directory record Official record
Conditions
Hepatitis C, Hepatocellular Carcinoma
Interventions
Mailed Outreach
Behavioral
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 2, 2020 · Synced Oct 21, 2026, 9:29 AM EDT
Completed Phase 1 Interventional Results available

An Open-Label Pharmacokinetics and Safety Study of Talazoparib (MDV3800)

NCT02997176
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
Talazoparib
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
11
States / cities
Alhambra, California • Bakersfield, California • Fullerton, California + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 25, 2021 · Synced Oct 21, 2026, 9:29 AM EDT
Terminated No phase listed Observational Results available

Computer Assisted Volumetric Analysis of CT-Identified Metastatic Pulmonary Or Hepatic Lesions

NCT00676455
View directory record Official record
Conditions
Metastatic Cancer
Interventions
Not listed
Lead sponsor
Lahey Clinic
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Burlington, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 10, 2013 · Synced Oct 21, 2026, 9:29 AM EDT
Completed Phase 2 Interventional Results available

Simvastatin in Preventing Liver Cancer in Patients With Liver Cirrhosis

NCT02968810
View directory record Official record
Conditions
Cirrhosis, Hepatocellular Carcinoma
Interventions
Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Placebo Administration, Questionnaire Administration, Simvastatin
Procedure · Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
3
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 21, 2026, 9:29 AM EDT
Terminated Phase 1Phase 2 Interventional

Safety and Efficacy of Intra-Arterial and Intra-Tumoral Ad-p53 With Capecitabine (Xeloda) or Anti-PD-1 in Liver Metastases of Solid Tumors and Recurrent Head and Neck Squamous Cell Cancer

NCT02842125
View directory record Official record
Conditions
Metastatic Solid Tumor Cancer, Recurrent Head and Neck Cancer
Interventions
Ad-P53, Xeloda, Keytruda, Opdivo
Drug
Lead sponsor
MultiVir, Inc.
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 2, 2020 · Synced Oct 21, 2026, 9:29 AM EDT
Completed Phase 4 Interventional Results available

Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking

NCT00365508
View directory record Official record
Conditions
Bladder Cancer, Cervical Cancer, Esophageal Cancer, Gastric Cancer, Head and Neck Cancer, Kidney Cancer, Leukemia, Liver Cancer, Lung Cancer, Pancreatic Cancer, Tobacco Use Disorder
Interventions
nicotine lozenge, nicotine patch
Drug
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Enrollment
642 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
10
States / cities
Washington D.C., District of Columbia • Miami Beach, Florida • Augusta, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2016 · Synced Oct 21, 2026, 9:29 AM EDT
Completed Phase 1 Interventional

Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu

NCT00004074
View directory record Official record
Conditions
Advanced Adult Primary Liver Cancer, Anaplastic Thyroid Cancer, Bone Metastases, Carcinoma of the Appendix, Distal Urethral Cancer, Fallopian Tube Cancer, Gastrinoma, Glucagonoma, Inflammatory Breast Cancer, Insulinoma, Liver Metastases, Localized Unresectable Adult Primary Liver Cancer, Lung Metastases, Male Breast Cancer, Malignant Pericardial Effusion, Malignant Pleural Effusion, Metastatic Gastrointestinal Carcinoid Tumor, Metastatic Parathyroid Cancer, Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter, Newly Diagnosed Carcinoma of Unknown Primary, Occult Non-small Cell Lung Cancer, Pancreatic Polypeptide Tumor, Primary Peritoneal Cavity Cancer, Proximal Urethral Cancer, Pulmonary Carcinoid Tumor, Recurrent Adenoid Cystic Carcinoma of the Oral Cavity, Recurrent Adrenocortical Carcinoma, Recurrent Adult Primary Liver Cancer, Recurrent Anal Cancer, Recurrent Bladder Cancer, Recurrent Breast Cancer, Recurrent Carcinoma of Unknown Primary, Recurrent Cervical Cancer, Recurrent Colon Cancer, Recurrent Endometrial Carcinoma, Recurrent Esophageal Cancer, Recurrent Extrahepatic Bile Duct Cancer, Recurrent Gallbladder Cancer, Recurrent Gastric Cancer, Recurrent Gastrointestinal Carcinoid Tumor, Recurrent Islet Cell Carcinoma, Recurrent Malignant Testicular Germ Cell Tumor, Recurrent Mucoepidermoid Carcinoma of the Oral Cavity, Recurrent Non-small Cell Lung Cancer, Recurrent Ovarian Epithelial Cancer, Recurrent Pancreatic Cancer, Recurrent Parathyroid Cancer, Recurrent Prostate Cancer, Recurrent Rectal Cancer, Recurrent Renal Cell Cancer, Recurrent Salivary Gland Cancer, Recurrent Small Intestine Cancer, Recurrent Squamous Cell Carcinoma of the Larynx, Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity, Recurrent Squamous Cell Carcinoma of the Nasopharynx, Recurrent Squamous Cell Carcinoma of the Oropharynx, Recurrent Thyroid Cancer, Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter, Recurrent Urethral Cancer, Recurrent Vaginal Cancer, Recurrent Vulvar Cancer, Skin Metastases, Small Intestine Adenocarcinoma, Somatostatinoma, Stage III Adenoid Cystic Carcinoma of the Oral Cavity, Stage III Adrenocortical Carcinoma, Stage III Bladder Cancer, Stage III Cervical Cancer, Stage III Colon Cancer, Stage III Endometrial Carcinoma, Stage III Esophageal Cancer, Stage III Follicular Thyroid Cancer, Stage III Gastric Cancer, Stage III Malignant Testicular Germ Cell Tumor, Stage III Mucoepidermoid Carcinoma of the Oral Cavity, Stage III Ovarian Epithelial Cancer, Stage III Pancreatic Cancer, Stage III Papillary Thyroid Cancer, Stage III Prostate Cancer, Stage III Rectal Cancer, Stage III Renal Cell Cancer, Stage III Salivary Gland Cancer, Stage III Squamous Cell Carcinoma of the Larynx, Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage III Squamous Cell Carcinoma of the Nasopharynx, Stage III Squamous Cell Carcinoma of the Oropharynx, Stage III Vaginal Cancer, Stage III Vulvar Cancer, Stage IIIA Anal Cancer, Stage IIIA Breast Cancer, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Anal Cancer, Stage IIIB Breast Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Adenoid Cystic Carcinoma of the Oral Cavity, Stage IV Adrenocortical Carcinoma, Stage IV Anal Cancer, Stage IV Bladder Cancer, Stage IV Breast Cancer, Stage IV Colon Cancer, Stage IV Endometrial Carcinoma, Stage IV Esophageal Cancer, Stage IV Follicular Thyroid Cancer, Stage IV Gastric Cancer, Stage IV Mucoepidermoid Carcinoma of the Oral Cavity, Stage IV Non-small Cell Lung Cancer, Stage IV Ovarian Epithelial Cancer, Stage IV Pancreatic Cancer, Stage IV Papillary Thyroid Cancer, Stage IV Prostate Cancer, Stage IV Rectal Cancer, Stage IV Renal Cell Cancer, Stage IV Salivary Gland Cancer, Stage IV Squamous Cell Carcinoma of the Larynx, Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IV Squamous Cell Carcinoma of the Nasopharynx, Stage IV Squamous Cell Carcinoma of the Oropharynx, Stage IVA Cervical Cancer, Stage IVA Vaginal Cancer, Stage IVB Cervical Cancer, Stage IVB Vaginal Cancer, Stage IVB Vulvar Cancer, Thyroid Gland Medullary Carcinoma, Unresectable Extrahepatic Bile Duct Cancer, Unresectable Gallbladder Cancer, Urethral Cancer Associated With Invasive Bladder Cancer, WDHA Syndrome
Interventions
recombinant interleukin-12, ABI-007/carboplatin/trastuzumab
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 28, 2013 · Synced Oct 21, 2026, 9:29 AM EDT
Recruiting Not applicable Interventional

Novel Method to Assess Hepatic Regeneration and Predict Hepatic Related Morbidity After Partial Hepatectomy

NCT06681818
View directory record Official record
Conditions
Liver Cancer Adult, Liver Regeneration
Interventions
carbon monoxide measurement via smokerlyzer
Other
Lead sponsor
Englewood Hospital and Medical Center
Other
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2039
U.S. locations
1
States / cities
Englewood, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 23, 2025 · Synced Oct 21, 2026, 9:29 AM EDT